Ranking Invest

IDEAYA Biosciences, Inc.

Segmento: Healthcare IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Indicadores Básicos

Valor de Mercado

$ 2.11 Bi

IVR

0.24

IVR2

-0.25

Índices de Previsibilidade

Faturamento

0.72

Lucro

0.53

Margem

0.91

Índices de Tendência

Faturamento

-8.11

Lucro

-10.91

Margem

2.00

Índices de Endividamento

DIV/PAT

-0.10

DIV/L4T

0.34

Dívida Líquida

-$ 104.03 Mi

Patrimônio Líquido

$ 1.02 Bi

L4T

-$ 306.31 Mi

MM4T

-465.40%

Dívidas
Dividendos
Cotação: $24.05

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre